Time to lymphoma treatment within 24 months in ‘watch and wait’ follicular lymphoma is associated with inferior outcomes: A multicentre analysis
Year: 2024
Type: article
Study design: Observational Study
Abstract: Summary Some ‘watch and wait’ (W&W) FL patients suffer from rapid progression in a short term. Herein, we sought to identify these patients and also develop a risk score to screen them at diagnosis. Between 2008 and 2022, a total of 411 FL patients managed by the W&W strategy from 16 cancer centres were retrospectively enrolled in this study, and their time to lymphoma treatment (TLT) and progression‐free survival (PFS) were evaluated. Thirty‐five percent of W&W FL patients experienced TLT within 24 months (TLT24) after diagnosis. Their 5‐year PFS rate was significantly lower than those without treatment at 24 months (62.3% vs. 89.5%). In multivariable analysis, five factors were identified as independent predictors of TLT24: stages III–IV, β2 microglobulin ≥3 mg/L, lymphocyte‐to‐monocyte ratio <3.8, bone marrow involvement and spleen enlargement (above umbilical line). Their AUCs for TLT24 were 0.76 (95% CI, 0.70–0.82) in the training cohort and 0.76 (95% CI, 0.67–0.85) in the validation cohort respectively. Risk groups were also associated with PFS (p < 0.001). In FL patients initially managed by W&W, TLT24 was associated with poor outcomes. This multivariable model helps screening for predicting TLT24, which may be useful to identify candidates for early interventional treatment.
Source: British Journal of Haematology
DOI: 10.1111/bjh.19770
Authors: Jing Liu, Fenghua Gao, Tingting Zhang, Jiesong Wang, Zhiming Li, Lihong Liu, Hui Zhou, Xudong Zhang, Xiuhua Sun, Wei Zhang, Bing Xu, Liping Su, Shujuan Wen, Rong Tao, Ou Bai, Liqun Zou, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Yuqin Song, Qingyuan Zhang, Xianhuo Wang, Huilai Zhang
Institutions: Tianjin Medical University Cancer Institute and Hospital, Cangzhou Central Hospital, Tianjin Medical University, Peking University Third Hospital, Shanxi Medical University, Shanxi Academy of Medical Sciences, Fujian Medical University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Fourth Hospital of Hebei Medical University, Central South University, Hunan Cancer Hospital, First Affiliated Hospital of Zhengzhou University, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Xiamen University, First Affiliated Hospital of Xiamen University, Shanxi Provincial Cancer Hospital, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University, Fudan University Shanghai Cancer Center, First Hospital of Jilin University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Peking University Cancer Hospital, Third Affiliated Hospital of Harbin Medical University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4402933435